174 related articles for article (PubMed ID: 35477539)
1. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.
Corry SM; McCorry AM; Lannagan TR; Leonard NA; Fisher NC; Byrne RM; Tsantoulis P; Cortes-Lavaud X; Amirkhah R; Redmond KL; McCooey AJ; Malla SB; Rogan E; Sakhnevych S; Gillespie MA; White M; Richman SD; Jackstadt RF; Campbell AD; Maguire S; ; McDade SS; Longley DB; Loughrey MB; Coleman HG; Kerr EM; Tejpar S; Maughan T; Leedham SJ; Small DM; Ryan AE; Sansom OJ; Lawler M; Dunne PD
Gut; 2022 Dec; 71(12):2502-2517. PubMed ID: 35477539
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
3. A stroma-related lncRNA panel for predicting recurrence and adjuvant chemotherapy benefit in patients with early-stage colon cancer.
Zhou R; Sun H; Zheng S; Zhang J; Zeng D; Wu J; Huang Z; Rong X; Bin J; Liao Y; Shi M; Liao W
J Cell Mol Med; 2020 Mar; 24(5):3229-3241. PubMed ID: 31989761
[TBL] [Abstract][Full Text] [Related]
4. Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer.
Chida S; Okayama H; Noda M; Saito K; Nakajima T; Aoto K; Hayase S; Momma T; Ohki S; Kono K; Takenoshita S
Carcinogenesis; 2016 Sep; 37(9):878-887. PubMed ID: 27287872
[TBL] [Abstract][Full Text] [Related]
5. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE
Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119
[TBL] [Abstract][Full Text] [Related]
6. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial.
Zunder S; van der Wilk P; Gelderblom H; Dekker T; Mancao C; Kiialainen A; Putter H; Tollenaar R; Mesker W
Cell Oncol (Dordr); 2019 Oct; 42(5):717-725. PubMed ID: 31102145
[TBL] [Abstract][Full Text] [Related]
7. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
8. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
10. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.
Strous MTA; Faes TKE; Gubbels ALHM; van der Linden RLA; Mesker WE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; Vogelaar FJ; de Bruïne AP
Clin Transl Oncol; 2022 Jun; 24(6):1047-1058. PubMed ID: 35064453
[TBL] [Abstract][Full Text] [Related]
11. Tumour and stroma RNA signatures predict more accurately distant recurrence than clinicopathological factors in resected pancreatic adenocarcinoma.
Hilmi M; Cros J; Puleo F; Augustin J; Emile JF; Svrcek M; Hammel P; Arsenijevic T; Van Laethem JL; Bachet JB; Nicolle R
Eur J Cancer; 2021 May; 148():171-180. PubMed ID: 33743485
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
13. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
14. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
Huijbers A; Tollenaar RA; v Pelt GW; Zeestraten EC; Dutton S; McConkey CC; Domingo E; Smit VT; Midgley R; Warren BF; Johnstone EC; Kerr DJ; Mesker WE
Ann Oncol; 2013 Jan; 24(1):179-85. PubMed ID: 22865778
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of tumour-stroma ratio in early-stage oral tongue cancers.
Almangush A; Heikkinen I; Bakhti N; Mäkinen LK; Kauppila JH; Pukkila M; Hagström J; Laranne J; Soini Y; Kowalski LP; Grénman R; Haglund C; Mäkitie AA; Coletta RD; Leivo I; Salo T
Histopathology; 2018 Jun; 72(7):1128-1135. PubMed ID: 29427291
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis.
Zhou Y; Guo Y; Wang Y
IET Syst Biol; 2022 Apr; 16(2):72-83. PubMed ID: 35352485
[TBL] [Abstract][Full Text] [Related]
18. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
19. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
20. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma.
Wang K; Ma W; Wang J; Yu L; Zhang X; Wang Z; Tan B; Wang N; Bai B; Yang S; Liu H; Zhu S; Cheng Y
J Thorac Oncol; 2012 Sep; 7(9):1457-61. PubMed ID: 22843085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
